Examine how the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 addresses the shortcomings of its voluntary predecessor. Does a non-statutory code suffice to regulate pharma-doctor relationships in India?

Q. Examine how the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 addresses the shortcomings of its voluntary predecessor. Does a non-statutory code suffice to regulate pharma-doctor relationships in India? (15 marks, 250-350 words)

Notified on 12 March 2024 by the Department of Pharmaceuticals, UCPMP 2024 superseded the voluntary UCPMP 2015 [1][3]. It marks a shift from industry self-regulation to government-supervised accountability in pharma–doctor interactions, though its status as a "Code" rather than a statute caps its bite.

Shortcomings of UCPMP 2015 - Voluntary adoption: the Code was drafted for voluntary compliance by associations, with no binding obligation on firms [2]. - Self-policing: complaints went to association-level Ethics Committees (ECPMP) with review by the Apex Ethics Committee (AECPMP) — the industry judging itself [2]. - No external appeal or disclosure: the government merely forwarded perceived violations to associations for "necessary action" [2].

How UCPMP 2024 responds - Mandatory character, drawing on the WHO Ethical Criteria for Medicinal Drug Promotion, giving it an internationally benchmarked standard [1]. - Explicit prohibitions on gifts, monetary benefits and hospitality to doctors/RMPs and their family members [1]. - Institutional accountability: mandatory Ethics Officers and self-declaration of adherence by companies [1][4]. - Financial transparency: disclosure of expenditure on CME conferences, seminars and workshops [1]. - External oversight: appeals lie with the Department of Pharmaceuticals, which has issued reasoned orders — e.g. the Apex Committee order of 23.12.2024 in the AbbVie Healthcare case [5]. - A September 2025 amendment further streamlined implementation and disclosure requirements [4].

Does a non-statutory code suffice? Only partially. First-tier adjudication still rests with pharma associations, sanctions remain largely reputational (reprimand, recovery of benefits, corrective statements) rather than penal, and the doctor's side is governed separately under the IMC (Professional Conduct) Regulations, 2002 — creating regulatory duality [1].

UCPMP 2024 therefore closes the enforcement and transparency gaps of 2015 without closing the statutory gap. Placing the Code on a legislative footing, with independent first-tier adjudication and deterrent penalties, would align pharmaceutical marketing with the Directive Principle under Article 47 and with SDG-3's goal of affordable, rational healthcare.

(~330 words)

Sources: 1. Uniform Code of Pharmaceuticals Marketing Practices 2024 to prevent unethical marketing (PIB) — mandatory character, WHO criteria basis, gift/hospitality ban, CME expenditure disclosure, two-tier complaint-and-appeal structure, penalties, IMC Regulations 2002 2. Uniform Code of Pharmaceutical Marketing Practices (PIB) — UCPMP 2015 as a voluntary code; ECPMP and Apex Ethics Committee (AECPMP) at association level; complaints forwarded to associations 3. Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 – reg, Department of Pharmaceuticals — notification of UCPMP 2024 on 12.03.2024 4. Uniform Code for Marketing Practices (PIB) — Ethics Officers, self-declaration, and the September 2025 amendment 5. Apex Committee Order dated 23.12.2024 in the case of M/s AbbVie Healthcare India Pvt. Ltd. under UCPMP 2024 — Department-level appellate adjudication in practice